OTCMKTS:STDAF STADA Arzneimittel Aktiengesellschaft (STDAF) Stock Price, News & Analysis $110.42 0.00 (0.00%) As of 10/24/2022 Add Compare Share Share Stock Analysis Stock AnalysisBuy This Stock About STADA Arzneimittel Aktiengesellschaft Stock (OTCMKTS:STDAF) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get STDAF alerts:Sign Up Key Stats Today's Range$110.42▼$110.4250-Day Range$110.42▼$110.4252-Week Range$75.15▼$115.00VolumeN/AAverage Volume180 shsMarket Capitalization$6.88 billionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview STADA is a publicly traded, international company with a focus on the healthcare market, especially the pharmaceutical and in particular the generics market. Read More Receive STDAF Stock News and Ratings via Email Sign-up to receive the latest news and ratings for STADA Arzneimittel Aktiengesellschaft and its competitors with MarketBeat's FREE daily newsletter. Email Address STDAF Stock News HeadlinesSTAFF NEWSFebruary 22, 2024 | washingtonpost.comKPLUY K+S AktiengesellschaftJanuary 10, 2024 | seekingalpha.comMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tariffs just lit the fuse. Millions of investors are blindsided as stocks plunge… but this is only Phase 1. If you're still holding the wrong assets, you could lose 30% or more in the coming weeks.August 25 at 2:00 AM | American Alternative (Ad)KPLUY K+S AktiengesellschaftJanuary 10, 2024 | seekingalpha.comSTADA Arzneimittel AG V (SAZA)July 21, 2023 | investing.comCBI hired 'toxic' staff and failed to sack offendersMay 30, 2023 | bbc.co.ukSartorius Aktiengesellschaft 2022 Q4 - Results - Earnings Call PresentationJanuary 28, 2023 | seekingalpha.comSee More Headlines STDAF Stock Analysis - Frequently Asked Questions How have STDAF shares performed this year? STADA Arzneimittel Aktiengesellschaft's stock was trading at $110.42 at the beginning of the year. Since then, STDAF stock has increased by 0.0% and is now trading at $110.42. How do I buy shares of STADA Arzneimittel Aktiengesellschaft? Shares of STDAF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Company Calendar Today8/25/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Medicinals & Botanicals Sub-IndustryN/A Current SymbolOTCMKTS:STDAF Previous SymbolNASDAQ:STDAF CIKN/A Webwww.stada.com Phone(496) 101-6030Fax49-61-0160-3259Employees12,500Year Founded1895Profitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity Ratio2.23 Current Ratio1.54 Quick Ratio0.99 Sales & Book Value Annual Sales$3.84 billion Price / Sales1.79 Cash Flow$11.12 per share Price / Cash Flow9.93 Book Value$23.11 per share Price / Book4.78Miscellaneous Outstanding Shares62,342,000Free FloatN/AMarket Cap$6.88 billion OptionableNot Optionable Beta0.38 Social Links 7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free Report This page (OTCMKTS:STDAF) was last updated on 8/25/2025 by MarketBeat.com Staff From Our PartnersBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredThe $7 company helping Nvidia build the world’s first trillion-dollar robot …Michael Robinson has been at the forefront of the technology market for over 40 years. Spotting some profit...Weiss Ratings | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding STADA Arzneimittel Aktiengesellschaft Please log in to your account or sign up in order to add this asset to your watchlist. Share STADA Arzneimittel Aktiengesellschaft With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access